Clinical trial · Observational
Changes in Muscle Tissue in Patients With Pancreatic Cancer
Pilot Study of Changes in Fat-Free Mass in Pancreatic Carcinoma Patients
NCT00369460CI-TRIAL-00019427completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Measuring changes in muscle tissue in patients with cancer may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future. PURPOSE: This pilot study is evaluating changes in muscle tissue in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| physiologic testing | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Fat-free mass (FFM)
- timeFrame
- Patients will have body mass index measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
- measure
- Correlation of changes in FFM with survival at 6 months
- timeFrame
- at 6 months
- measure
- Incidence of lymphocytopenia
- timeFrame
- Total lymphocyte count measured before start of cancer treatment and at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
- measure
- Correlation of pretreatment total lymphocyte count, treatment response, and survival at 6 months
- timeFrame
- at 6 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Biopsy-proven inoperable locally advanced or metastatic pancreatic adenocarcinoma
PATIENT CHARACTERISTICS:
* ECOG performance status 0-3
* Must be able to stand unassisted on a scale
* Must not have pacemaker or implanted defibrillator
PRIOR CONCURRENT THERAPY:
* Prior chemotherapy or radiotherapy allowed
* No concurrent use of any of the following:
* Corticosteroids
* Steroids as anti-emetics associated with chemotherapy allowed
* Anabolic steroids
* Thalidomide
* Megesterol
* Eicosapentaenoic acid (EPA)
* Nutritional supplements without EPA allowed
* Juven
* Concurrent enrollment in other clinical trials allowedReferences
Publications (0)
Data not yet available
No reference posted for this study.